Elite Pharma Inc
Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals. The company operates through Abbreviated New Drug Applications for Generic Pharmaceuticals and New Drug Applications for Branded Pharmaceuticals segments. It owns, licenses, manufactures, and sales of generic, oral do… Read more
Market Cap & Net Worth: Elite Pharma Inc (ELTP)
Elite Pharma Inc (OTCQB:ELTP) has a market capitalization of $342.39 Million ($342.39 Million) as of March 18, 2026. Listed on the OTCQB stock exchange, this USA-based company holds position #13501 globally and #5578 in its home market, demonstrating a -31.98% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Elite Pharma Inc's stock price $0.32 by its total outstanding shares 1070963108 (1.07 Billion).
Elite Pharma Inc Market Cap History: 2015 to 2025
Elite Pharma Inc's market capitalization history from 2015 to 2025. Data shows growth from $438.02 Million to $342.39 Million (4.03% CAGR).
Elite Pharma Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Elite Pharma Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
4.07x
Elite Pharma Inc's market cap is 4.07 times its annual revenue
1.01x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $162.79 Million | $12.50 Million | -$683.01K | 13.02x | N/A |
| 2017 | $98.53 Million | $9.64 Million | $3.81 Million | 10.22x | 25.85x |
| 2018 | $80.22 Million | $7.46 Million | -$3.67 Million | 10.75x | N/A |
| 2019 | $99.06 Million | $7.57 Million | -$9.28 Million | 13.09x | N/A |
| 2020 | $55.90 Million | $17.99 Million | -$2.24 Million | 3.11x | N/A |
| 2021 | $32.13 Million | $25.38 Million | $5.09 Million | 1.27x | 6.31x |
| 2022 | $32.13 Million | $32.26 Million | $8.90 Million | 1.00x | 3.61x |
| 2023 | $149.93 Million | $34.16 Billion | $4.41 Billion | 0.00x | 0.03x |
| 2024 | $631.87 Million | $56.63 Million | $20.11 Million | 11.16x | 31.42x |
| 2025 | $342.39 Million | $84.04 Million | -$4.31 Million | 4.07x | N/A |
Competitor Companies of ELTP by Market Capitalization
Companies near Elite Pharma Inc in the global market cap rankings as of March 18, 2026.
Key companies related to Elite Pharma Inc by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #423 globally with a market cap of $51.97 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #455 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #719 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #423 | Zoetis Inc | NYSE:ZTS | $51.97 Billion | $118.15 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.46 |
| #455 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #719 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Elite Pharma Inc Historical Marketcap From 2015 to 2025
Between 2015 and today, Elite Pharma Inc's market cap moved from $438.02 Million to $ 342.39 Million, with a yearly change of 4.03%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $342.39 Million | -45.81% |
| 2024 | $631.87 Million | +321.43% |
| 2023 | $149.93 Million | +366.67% |
| 2022 | $32.13 Million | 0.00% |
| 2021 | $32.13 Million | -42.53% |
| 2020 | $55.90 Million | -43.57% |
| 2019 | $99.06 Million | +23.50% |
| 2018 | $80.22 Million | -18.59% |
| 2017 | $98.53 Million | -39.47% |
| 2016 | $162.79 Million | -62.84% |
| 2015 | $438.02 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Elite Pharma Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $342.39 Million USD |
| MoneyControl | $342.39 Million USD |
| MarketWatch | $342.39 Million USD |
| marketcap.company | $342.39 Million USD |
| Reuters | $342.39 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.